Edwards Lifesciences

NYSE: EW

Stock price

91.79 USD

(+Infinity%) NaN day

By default your notes are visible only to you.

72.3

52-week range

96.2

91.79

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

2 %

Dividend Yield TTM

-

Market cap $

$ 52,853

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

48.8

Price / Book TTM

5.1

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

(0.7)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

17.6 %

(14) %

158.6 %

Free cash flow per share growth

371.1 %

122.6 %

239.8 %

Earnings per share growth

(73.7) %

40.8 %

144 %

Founded: 1,958

Employees: 15,800

Business Summary:Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Fair Value Reference Estimate

Latest Earnings Call Takeaways

Annual Reports, Presentations And IR Contacts

Go to the website

Edwards Lifesciences — Financial Overview, Stock Price, Market Cap

Edwards Lifesciences is a company. Founded in 1958. As of July 14, 2026, the company's market capitalization is $52852682000 with a current stock price of $91.79.